CNC

Health coverage company Centene (NYSE:CNC) announced better-than-expected revenue in Q3 2026, with sales up 1.9% year on year to $50.65 billion. The company’s full-year revenue guidance of $198.5 billion at the midpoint came in 1.3% above analysts’ estimates.

Centene delivered better-than-expected results in Q3 2026, buoyed by strength in its Medicare and Marketplace businesses.

Centene reported Q3 2026 revenue of US$50.65b with a GAAP net loss of US$71m, while adjusted EPS of US$0.58 exceeded market expectations and supported higher full year earnings and revenue guidance.

Centene earnings beat and outlook reset Centene (CNC) just delivered third quarter earnings that topped analyst expectations, with Medicare results standing out and management raising both revenue and earnings guidance for the rest of 2026.

CNC raises its 2026 earnings outlook after Q3 results beat estimates, as Medicare recovery accelerates despite Medicaid enrollment and margin risks.

Centene stock is drifting lower today, down about 1% in afternoon trade around US$67. The move is mild, yet the latest Q3 2026 report is anything but dull.

Does Centene (CNC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Centene (NYSE:CNC) subsidiary Ambetter Health has outlined a significant expansion of its 2027 Marketplace health plans across new regions. The 2027 lineup introduces condition specific plans aimed at members managing heart failure, diabetes, asthma and COPD.

Centene has more than doubled over the past year, and with the stock last closing at US$68.71, the obvious question is whether that move is backed up by the insurer's earnings power.

Centene (NYSE:CNC) raised its full-year 2026 adjusted earnings outlook after reporting third-quarter results that exceeded its prior expectations, supported by stronger Medicare performance and in-line execution in Medicaid and commercial insurance.

Medicare Advantage reaches breakeven ahead of schedule as Medicaid membership declines.